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The PI3K-AKT, mTOR-p70S6 kinase and AMPK
pathways play distinct and critical roles in metabolic
regulation. Each pathway is necessary for leptin’s
anorexigenic effects in the hypothalamus. Here we
show that these pathways converge in an integrated
phosphorylation cascade to mediate leptin action in
the hypothalamus. We identify serine491 on a2AMPK
as the site of convergence and show that p70S6
kinase forms a complex with a2AMPK, resulting
in phosphorylation on serine491. Blocking a2AMPK-
serine491 phosphorylation increases hypothalamic
AMPK activity, food intake, and body weight.
Serine491 phosphorylation is necessary for leptin’s
effects on hypothalamic a2AMPK activity, neuropep-
tide expression, food intake, and body weight. These
results identify an inhibitory AMPK kinase, p70S6
kinase, and demonstrate that AMPK is a substrate
for mTOR-p70S6 kinase. This discovery has broad
biologic implications since mTOR-p70S6 kinase and
AMPK have multiple, fundamental and generally
opposing cellular effects that regulate metabolism,
cell growth, and development.
INTRODUCTION
Obesity has reached epidemic proportions worldwide and
increases the risk for diabetes, cardiovascular disease, and early
mortality. Maintaining normal body weight requires tight control
of energy homeostasis, which necessitates a constant flow of
metabolic input to the hypothalamus in the form of nutrients
and hormones. Specific signal transduction pathways have
evolved to process afferent hypothalamic input into adaptive
changes in food intake and energy expenditure (Morton et al.,
2006). Leptin, an adipocyte-derived anorexigenic factor, relays
the status of fat stores to the hypothalamus through multiple
signaling pathways resulting in regulation of food intake and
body weight (Friedman and Halaas, 1998; Halaas et al., 1995;
Morton et al., 2006). Binding of leptin to its cytokine-like receptor
activates Jak2, which phosphorylates the receptor on tyrosine104 Cell Metabolism 16, 104–112, July 3, 2012 ª2012 Elsevier Inc.residues that have been specifically mapped to effects on food
intake, energy expenditure, and reproduction (Myers et al.,
2009; Villanueva and Myers, 2008). While Stat3-regulated gene
transcription is a well-established mechanism mediating many
of leptin’s actions (Hill et al., 2008; Niswender et al., 2001), the
PI3K-AKT, mTOR-p70S6 kinase (p70S6K), and AMPK pathways
mediate important, rapid effects of leptin. How these pathways
integrate to produce leptin’s anorexigenic effects is a critical
question for understanding energy balance.
The heterotrimeric AMPK complex is composed of an a
catalytic subunit and two regulatory subunits, b and g. AMPK
is a cellular ‘‘energy gauge’’ that responds to increases in the
AMP:ATP ratio (Hardie et al., 2003) and plays a fundamental
role in cell growth and metabolism. Alterations in the AMPK
pathway cause diseases ranging from cardiac arrhythmias to
cancer (Hardie, 2007; Steinberg and Kemp, 2009). In the hypo-
thalamus, AMPK acts as a systemic energy sensor. Inhibition
of hypothalamic a2AMPK activity is necessary for leptin to
reduce food intake and body weight (Minokoshi et al., 2004).
AMPK activation requires phosphorylation at threonine172 of
the a catalytic subunit by upstream kinases (Hardie, 2007).
Recently, other phosphorylation sites on the a and b subunits
have been shown to alter kinase activity (Djouder et al., 2010;
Horman et al., 2006; Hurley et al., 2006; Soltys et al., 2006;
Warden et al., 2001), thereby broadening the potential mecha-
nisms for regulating AMPK activity and its biologic effects.
Phosphorylation of AMPK a subunits on serine485/491 inhibits
AMPK threonine172 phosphorylation and AMPK activity (Horman
et al., 2006; Hurley et al., 2006). Here we show that phosphory-
lation of a2AMPK on serine491 in the hypothalamus inhibits its
activity and is critical for leptin action on food intake and body
weight. We further show that p70S6K is an inhibitory AMPK
kinase that forms a complex with the a2AMPK catalytic subunit
and directly phosphorylates it on serine491. This is a critical inte-
gration point where multiple signaling pathways converge in the
hypothalamus to mediate leptin action.
RESULTS
Leptin and Refeeding Decrease a2AMPK Activity and
Induce AMPK Serine485/491 Phosphorylation in the
Hypothalamus
To determine the mechanisms by which leptin inhibits hypo-
thalamic a2AMPK activity and regulates body weight, we
Cell Metabolism
p70S6 Kinase Is an Inhibitory AMPK Kinaseinvestigated the phosphorylation of serine491 on a2AMPK in
response to leptin intracerebroventricularly (i.c.v.). We studied
this site because increased serine485/491 phosphorylation is
associated with decreased AMPK activity (Hurley et al., 2006;
Pulinilkunnil et al., 2011).We focused on a2AMPK because leptin
alters the activity of a2 and not a1AMPK (Minokoshi et al., 2002,
2004). In normal mice, leptin acutely decreases a2AMPK activity
in arcuate (ARC), ventromedial (VMH)/dorsomedial (DMH), and
paraventricular (PVN) hypothalamus while stimulating AMPK
serine485/491 phosphorylation (Figure 1A, also analyzed in VMH
and DMH separately—Figure S1A available online). While
we did not see a change in acetyl-CoA carboxylase (ACC)
phosphorylation at this time point (data not shown), we did
see increased phosphorylation of p70S6Kinase, another AMPK
target and its downstream target, S6 (Figure S1B). In lateral
hypothalamus (LH), where a2AMPK activity is not inhibited
by leptin, AMPK serine phosphorylation is not increased (Fig-
ure 1A). To further understand the physiologic regulation of
aAMPK serine485/491, we assessed the effects of fasting and re-
feeding. aAMPK serine485/491 phosphorylation was low in hypo-
thalamus of overnight fasted mice and increased 75% with
refeeding (6 hr) in conjunction with inhibition of a2AMPK activity
(Figure S1C).
Leptin Inhibits a2AMPKActivity by Phosphorylating It on
Serine491
To determine whether serine491 phosphorylation is critical for
leptin-induced inhibition of a2AMPK activity, we introduced a
phospho-defective a2AMPKmutant (S491A) into GT1-7 neurons
that normally express functional leptin receptors (Magni et al.,
1999). Overexpression of WT a2AMPK in GT1-7 cells does not
change a2AMPK activity (data not shown). Leptin stimulated
serine491 phosphorylation of exogenous WT but not S491A
a2AMPK (Figures 1B and 1C, top panel). Leptin inhibited
a2AMPK activity (Figure 1C, middle panel) in cells expressing
WT but not S491A a2AMPK, demonstrating that serine491
phosphorylation (Figure 1B) is necessary for a2AMPK inhibition
by leptin. These changes in a2AMPK serine491 phosphorylation
and the leptin-induced inhibition of a2AMPK activity were not
associated with changes in AMPK threonine172 phosphorylation.
A phosphomimetic a2AMPK mutant (S491D) mimicked the
effect of leptin to inhibit a2AMPK activity (Figure S1D) underscor-
ing the importance of this phosphorylation site. Blocking the lep-
tin-induced a2AMPK serine491 phosphorylation inhibited ACC
phosphorylation (Figures 1B and 1C, bottom panel). The mech-
anism by which phosphorylation of a2AMPK on serine491 inhibits
AMPK activity does not involve changes in affinity for the b and g
subunits since we found the same amount of b1, g1, and g2
subunits complexed with wild-type and S491A a2 subunits
(Figure S1E).
Hypothalamic a2AMPK Serine491 Phosphorylation
Regulates Food Intake and Body Weight
To test the effect of hypothalamic serine491 phosphorylation
on food intake and body weight, we introduced the WT and
S491A mutant of a2AMPK into the mediobasal (ARC, VMH,
DMH) hypothalamus of normal mice using recombinant adenovi-
ruses. This hypothalamic region was chosen because of its crit-
ical role in regulation of food intake and body weight (Mortonet al., 2006; Myers et al., 2009) and because leptin stimulates
aAMPK serine485/491 phosphorylation in this region (Figure 1A).
Western blotting of individual hypothalamic nuclei showed
expression of WT and S491A a2AMPK in the ARC and VMH/
DMH but not in PVN or LH (Figure 1D). Consistent with these
results, immunohistochemistry showed expression in ARC,
VMH, and DMH but not in other hypothalamic areas (Fig-
ure 1E). While the exogenous and endogenous WT AMPK were
phosphorylated on serine491, introduction of S491A a2AMPK
completely blocked the phosphorylation of exogenous a2AMPK
on serine491 in the in vivo experiments (Figure 1F, top panel).
Obliterating the phosphorylation of a2AMPK on serine491 in
ARC and VMH/DMH did not affect threonine172 phosphorylation
(Figure 1F, second panel).
Next, we tested the effect of S491A a2AMPK on body weight
and food intake. Transient weight loss was seen as expected
after intrahypothalamic (IHP) injections of adenoviral constructs.
Expression of WT a2AMPK did not affect body weight or food
intake compared to empty virus control (data not shown).
However, mice expressing S491A a2AMPK maintained higher
weight than controls (Figure 1G), which could at least partially
be explained by greater food intake (Figure 1H). Thus, alteration
of serine491 phosphorylation of hypothalamic a2AMPK is suffi-
cient to regulate food intake and body weight.
Phosphorylation of a2AMPK on Serine491 in the
Hypothalamus Is Necessary for Leptin’s Effect on Food
Intake and Body Weight
To determine whether phosphorylation of a2AMPK on serine491
is required for leptin’s effect on food intake and body weight,
we injected overnight-fasted mice expressing WT or S491A
a2AMPK in the mediobasal hypothalamus with leptin. In WT
mice, leptin decreased body weight by 1.67 g over 24 hr
compared to a 0.38 g increase in body weight in saline-injected
control mice (Figure 2A). In contrast, in mice expressing S491A
a2AMPK, leptin did not reduce body weight (Figure 2A). Effects
on food intake paralleled the effects on body weight. In saline-
injected mice, food intake increased as expected after overnight
fasting (Figure 2B). Leptin decreased 24 hr food intake from
5.97 ± 0.22 g to 3.43 g ± 0.35 in WT a2AMPK-expressing
mice but had no effect in S491A AMPK-expressing mice (Fig-
ure 2B). This resistance to leptin’s effects could be explained
by defective AMPK serine491 phosphorylation since leptin
increased serine491 phosphorylation (Figure 2C) and inhibited
a2AMPK activity (Figure 2D) in ARC and VMH/DMH of mice
injected with WT a2AMPK but not with S491A a2AMPK. Thus,
phosphorylation of serine491 in mediobasal hypothalamus is
necessary for leptin to inhibit a2AMPK activity in vivo and for
leptin’s anorexigenic and weight loss effects; failure to modulate
phosphorylation on this site appears to cause resistance to
leptin’s effects on AMPK activity and food intake.
We sought to determine whether serine491 phosphorylation
is involved in chronic leptin resistance such as that induced
by high-fat diet (HFD). In HFD, hypothalamic a2AMPK activity
is already low, and leptin does not lower it further (Martin
et al., 2006), indicating that modulation of a2AMPK activity is
critical for leptin’s anorexigenic effects. HFD increased AMPK
serine485/491 phosphorylation and inhibited a2AMPK activity
in basomedial hypothalamus and PVN (Figure S2). In lateralCell Metabolism 16, 104–112, July 3, 2012 ª2012 Elsevier Inc. 105
Figure 1. Leptin Induces Serine491 Phosphorylation of a2AMPK in Hypothalamus to Regulate Food Intake and Body Weight
(A) a2AMPK activity, aAMPK serine485/491/a2AMPK, and AMPK threonine172 after saline or leptin injection (20 ng i.c.v.; 3 hr) in overnight fasted mice (n = 5–8/
group). *p < 0.05 versus saline.
(B and C) GT1-7 neurons were transfected with Flag-WT or Flag-S491A-a2AMPK and treated with 0.5 mg/ml leptin (+) or vehicle (–) for 2 hr. Cell extracts were
immunoprecipitated with a2AMPK antibody for (B and C, top panel) pSerine485/491/a2AMPK and pThreonine172 or (C, middle panel) a2AMPK activity or (B and C,
lower panel) analyzed for pACCab/ACCab and actin. *p < 0.05 versus all other groups.
(D) Flag-WT and Flag-S491A a2AMPK expression in hypothalamic nuclei 8 days after adenovirus injection.
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Figure 2. Expression of S491A-a2AMPK in hypothalamus blocks leptin’s effect on food intake and body weight
(A and B) Body weight change (A) and food intake (B) 24 hr after leptin (5 mg/kg X2 injections i.p.) (n = 12/group). *p < 0.05 versus all other groups.
(C) a2AMPK serine491 phosphorylation in hypothalamic nuclei after leptin (5mg/kg i.p.) injected 24, 12 and 3 hr before sacrifice on day 8 after adenovirus injection.
ARC and VMH/DMH were subjected to immunoprecipitation with a2AMPK antibody. Endogenous and exogenous (Flag-WT or Flag-S491A) a2AMPK were
detected by immunoblotting.
(D) a2AMPK activity in hypothalamic nuclei used in (C) (n = 8/group). *p < 0.05 versus all other groups.
(E) pSTAT3 in hypothalamic nuclei used in (C) (n = 6/group). #p < 0.05 versus saline injection.
(F) S491A blocks leptin’s effect onAgRP andPOMCmRNA in ARC and VMH/DMHof fastedmice. *p < 0.05 versus fed formicewith same vector. #p < 0.05 versus
fasted saline for mice with same vector.
Data in all panels are shown as means ± SEM. See also Figure S2.
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not increased by HFD, a2AMPK activity is not suppressed
(Figure S2).
Interestingly, leptin-induced Stat3 phosphorylation was not
impaired by S491A-aAMPK (Figure 2E), similar to observa-
tions with constitutively active AMPK (Minokoshi et al.,
2004). Thus, biologic leptin resistance can be induced inde-
pendent of signaling through Stat3. To explore the mechanism
by which serine491 phosphorylation mediates the anorexigenic
effect of leptin, we examined hypothalamic neuropeptide(E) Immunohistochemistry with Flag antibody. Low (left) and high (middle) magni
injection with Flag-S491A-a2AMPK adenovirus (columns 1 and 2) or null adenov
(F) Hypothalamic extracts were subjected to immunoprecipitation with a2AMPK
a2AMPK phosphorylation was detected by immunoblotting.
(G and H) Changes in body weight and daily food intake after mediobasal hypo
group). *p < 0.05 versus mice expressing Flag-WT-a2AMPK.
Data in all panels are shown as means ± SEM. See also Figure S1.expression. In mice expressing WT a2AMPK, overnight fasting
stimulated AgRP while suppressing POMC messenger RNA
(mRNA) levels compared to ad libitum-fed mice. Leptin treat-
ment of fasted mice reversed these effects (Figure 2F). In
contrast, leptin failed to prevent the effect of fasting to
increase AgRP and inhibit POMC mRNA expression in
S491A a2AMPK-expressing mice (Figure 2F). Thus, the effects
of leptin-induced aAMPK serine491 phosphorphorylation may
be mediated by changes in hypothalamic neuropeptide
expression.fication of ARC and VMH/DMH (top), PVN (middle row), and LH (bottom) after
irus (Empty) (top right, high magnification) are shown.
antibody. Endogenous (Endo) and exogenous (Exo) (Flag-WT or Flag-S491A)
thalamic injection of Flag-WT or Flag-S491A a2AMPK adenovirus (n = 22-24/
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Figure 3. Leptin Stimulates aAMPK Serine485/491 Phosphorylation through PI3K-AKT Signaling
(A and B) i.c.v. injection of vehicle (DMSO) or LY294002 (0.1 nmol; 30min) followed by saline (–) or leptin (20 ng; 3 hr) (+) in overnight-fastedmice (n = 7/group). ARC
(A) and VMH/DMH (B) were analyzed for a2AMPK activity and aAMPK serine485/491/a2AMPK.
(C) GT1-7 neurons were treated with DMSO or LY294002 (20 mM) and 0.5 mg/ml leptin (+) or vehicle (–) for 2 hr and analyzed for a2AMPK activity and aAMPK
serine485/491/a2AMPK.
(D) GT1-7 neurons were transfected with CA- or DN-AKT or vector (Vec) and analyzed for a2AMPK activity and aAMPK serine485/491/a2AMPK.
(E) GT1-7 neurons were transfected with DN-AKT or vector and treated with 0.5 mg/ml leptin (+) or vehicle (–) for 2 hr. Cell extracts were analyzed for a2AMPK
activity and aAMPK serine485/491/a2AMPK. *p < 0.05 versus empty vector control. #p < 0.05 versus empty vector leptin.
(F) pS6K/S6K and pS6/S6 in hypothalamic nuclei after saline or leptin injection (20 ng i.c.v.; 3 hr) in overnight fasted mice (n = 6/group). *p < 0.05 versus saline.
Data in all panels are shown as means ± SEM. See also Figure S3.
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through PI3K-AKT Signaling
Because of the important biologic effects, we aimed to identify
the kinase(s) that mediates leptin-induced serine491 phosphory-
lation. Both PKA and AKT can induce phosphorylation of a1
and a2AMPK on serine485 and serine491, respectively, in cultured
cells, perfused heart, or BAT (Horman et al., 2006; Hurley et al.,
2006; Mankouri et al., 2010; Pulinilkunnil et al., 2011). We first
investigated thePI3K-AKTpathway in thehypothalamusbecause
it plays a major role in regulation of energy balance and is neces-
sary for leptin’s anorexigenic action (Hill et al., 2008; Niswender
et al., 2001; Xu et al., 2010). i.c.v. injection (30 min) of the PI3K
inhibitor LY294002, which diminished the anorexigenic effect
of leptin in previous studies (Morrison et al., 2005; Niswender
et al., 2001), blocked the effect of leptin to stimulate aAMPK
serine485/491 phosphorylation and to inhibit a2AMPK activity
in the ARC (Figure 3A) and VMH/DMH (Figure 3B).108 Cell Metabolism 16, 104–112, July 3, 2012 ª2012 Elsevier Inc.To determine whether PI3K stimulates serine485/491 phosphor-
ylation directly, we studied the effects in GT1-7 neurons. The
P13K inhibitor LY294002 blocked the effect of leptin to stimulate
serine485/491 phosphorylation and to inhibit a2AMPK activity
(Figure 3C). This effect of PI3K was confirmed with a second
inhibitor, wortmannin, which also blocked leptin’s effects (data
not shown). These effects are consistent with genetic studies
showing that disruption of PI3K signaling in hypothalamic
neurons in vivo blocks leptin action on food intake and body
weight (Al-Qassab et al., 2009).
To further elucidate the pathway involved in leptin-induced
serine491 phosphorylation of AMPK, we investigated the down-
stream target of PI3K, AKT (Manning and Cantley, 2007). Consti-
tutively active AKT (CA-AKT) increased aAMPK serine485/491
phosphorylation and inhibited a2AMPK activity inGT1-7 neurons
while DN-AKT decreased phosphorylation and increased
a2AMPK activity (Figure 3D). Furthermore, DN-AKT blocked
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tion of a2AMPK activity (Figure 3E), indicating that AKT activation
is necessary for leptin-induced aAMPK serine485/491 phosphory-
lation. A PKA inhibitor did not block the effect of leptin on
serine485/491 phosphorylation (Figure S3A) or a2AMPK activity
(Figure S3B), and a PKA activator had no effect on a2AMPK
activity (Figure S3C).
Leptin Inhibits a2AMPK Activity through p70S6K-
Dependent AMPK Serine485/491 Phosphorylation
Examination of the sequence flanking the serine 491 site on
a2AMPK revealed a proline in position 5 that renders this unfa-
vorable for direct phosphorylation by ACG kinases including AKT
and PKA (Kemp and Pearson, 1990; Manning and Cantley, 2007)
but acceptable for phosphorylation by p70S6K (Richardson
et al., 2004) (Figure S3D). Since Akt activates p70S6K through
the TSC-mTOR pathway (Zoncu et al., 2011), we hypothesized
that downstream to AKT, p70S6K is involved in the leptin
signaling pathway that phosphorylates a2AMPK on serine491.
To investigate this, we measured leptin-induced phosphoryla-
tion of p70S6K and its target S6 (Figure 3F) in hypothalamic
nuclei. Leptin acutely increased phosphorylation of p70S6K
and S6 in ARC, VMH/DMH, and PVN but not in the LH. (Fig-
ure 3F), suggesting that p70S6K could be mediating the effects
of the PI3K-AKT pathway on leptin-induced serine phosphoryla-
tion of AMPK.
We tested whether p70S6K can alter AMPK phosphorylation
directly. In GT1-7 neurons, CA-S6K1 phosphorylates aAMPK
at serine485/491 and does not affect the phosphorylation on
threonine172 (Figure 4A). An in vitro phosphorylation assay with
naked proteins demonstrates that recombinant S6K direct-
ly phosphorylates recombinant a2AMPK/b1/g1 complex on
serine491 but not on threonine172 of a2AMPK (Figure 4B).
This indicates that p70S6K is an AMPK kinase (AMPKK) and
unlike the known AMPKKs, LKB1 and CamKK2, p70S6K
phosphorylates aAMPKon serine and not threonine172. To deter-
mine whether p70S6K forms a complex with aAMPK similar
to the complexes formed by LKB1 and CaMKKb (Anderson
et al., 2008; Shaw et al., 2004), we immunoprecipitated the
endogenous a2AMPK subunit from brain extracts and identi-
fied p70S6K (Figure 4C). Since a1AMPK has the same S6K
consensus site, we verified whether S6K1 could also phosphor-
ylate a1AMPK. In addition to a2AMPK (Figures 4A and 4B),
CA-S6K1 also phosphorylates a1AMPK (Figure S4A).
To determine whether p70S6K is necessary for leptin-induced
aAMPK serine485/491 phosphorylation in the hypothalamus
in vivo, we injected S6K1 knockout (S6K1/) mice with saline
or leptin. Previous studies have shown that S6K1/ mice are
resistant to leptin’s anorectic action (Cota et al., 2008). Leptin
increased AMPK serine phosphorylation by 47%–53% in ARC
and VMH/DMH of WT mice but had no effect in the S6K1/
mice (Figure 4D). This suggests that p70S6K is necessary for
leptin-induced aAMPKserine485/491 phosphorylation in the hypo-
thalamus. Consistent with the effects observed in S6K1/mice,
suppression of p70S6K activity in the hypothalamus byDN-S6K1
blocks the effect of leptin to decrease food intake and body
weight (Blouet et al., 2008). To further study the role of S6K
in leptin signaling, we expressed DN-S6K1 in neurons followed
by leptin treatment. We first verified the effectiveness of DN-S6K1. In cells transfected with empty vector, leptin stimulated
p70S6K activity as indicated by increased phosphorylation of
the substrate S6 (Figure 4E). DN-S6K1 blocked leptin-induced
S6 phosphorylation, aAMPK serine485/491 phosphorylation, and
inhibition of a2AMPK activity (Figure 4E). This indicates that
p70S6K is necessary for leptin-induced serine491 phosphoryla-
tion ofa2AMPK. Thesechanges inAMPKserine485/491 phosphor-
ylation and a2AMPK activity were independent of alterations
in threonine172 phosphorylation (Figure 4E), consistent with our
data in the hypothalamus (Figure 1F). This indicates that modula-
tion of AMPK-serine491 phosphorylation can have a dominant
role in regulation of AMPK activity. To reinforce the involvement
of the mTOR-p70S6K pathway, we also tested the effect of
rapamycin, an inhibitor of mTOR complex 1, which also blocked
leptin-induced serine485/491 phosphorylation of aAMPK and inhi-
bition of AMPK activity (Figure 4F).
DISCUSSION
The emerging role of AMPK not only in the regulation of metab-
olism, but also cancer and development, emphasizes the impor-
tance of understanding the molecular mechanisms that regulate
its activity. We show that in the hypothalamus, phosphorylation
of a2AMPK on serine491 inhibits its kinase activity and is
sufficient to regulate food intake and body weight. Furthermore,
phosphorylation on this site is necessary for leptin action on
food intake and body weight. Threonine172 phosphorylation of
aAMPK is critical for its activation (Hardie, 2007; Steinberg and
Kemp, 2009). However, our studies demonstrate that aAMPK
activity can be inhibited by phosphorylation on serine485/491
independent of changes in threonine172 phosphorylation. There-
fore, serine485/491 phosphorylation is an ‘‘off switch’’ for AMPK
activity in addition to AMPK phosphatases (Hardie, 2007;
Sanders et al., 2007; Steinberg and Kemp, 2009).
Previous studies showed that leptin inhibits threonine172 phos-
phorylation in the hypothalamus (Gao et al., 2007; Andersson
et al., 2004), and in some cell culture models, serine485/491 phos-
phorylation is associated with reduced threonine172 phosphory-
lation (Hurley et al., 2006; Soltys et al., 2006). The fact that we
do not see this with leptin action in GT1-7 cells or in hypothal-
amus in vivo in this study and in previous studies (Martin et al.,
2006; Minokoshi et al., 2004), may result from methodological
differences. However, the immune complex assay demonstrates
that leptin reduces AMPK activity (Figures 1A and 1C). The
substrate for our AMP kinase assay consists of the 13 amino
acid residues around serine 79 of ACC, which is the unique
site on which AMPK phosphorylates ACC. Hence, the activity
assay measures the ability of AMPK to phosphorylate ACC and
this is reduced in response to leptin (Figures 1A and 1C).
mTOR and AMPK are both important nutrient sensors that
have broad and mostly opposing effects on metabolic function.
The current understanding is that AMPK is an upstream regulator
of mTOR, inhibiting its activity. Our study demonstrates that
p70S6K is also an AMPK kinase that directly phosphorylates
aAMPK at serine485/491, thereby inhibiting its activity. A previous
study showed activation of AMPK in muscle cells lacking S6K,
although the authors’ conclusion was that deletion of S6K stim-
ulates AMPK indirectly by increasing cellular AMP and inorganic
phosphate levels (Aguilar et al., 2007).Cell Metabolism 16, 104–112, July 3, 2012 ª2012 Elsevier Inc. 109
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Figure 4. Leptin Inhibits a2AMPK Activity through p70S6K-Dependent AMPK Serine485/491 Phosphorylation
(A) GT1-7 neurons were transfected with Empty, WT, or CA-S6K1 vectors. AMPK phosphorylation was analyzed by immunoblotting (n = 3/group).
(B) Recombinant a2AMPK/b1/g1 complex was incubated with active and inactive recombinant S6K. Phosphorylation of a2AMPK on serine491 and threonine172
and total a2AMPK were analyzed by immunoblotting.
(C) Brain extracts were subjected to immunoprecipitation with a2AMPK antibody (AB) and blotted for p70S6K (top) or a2AMPK (bottom).
(D) aAMPK serine485/491/a2AMPK in hypothalamic nuclei after saline or leptin injection (i.p.) in overnight-fastedWT and S6K1 (/) mice (n = 5–8/group). *p < 0.05
versus saline.
(E) GT1-7 neurons were transfected with DN-S6K1 or vector (Vec), treated with 0.5 mg/ml leptin (+) or vehicle (–) for 2 hr and immunoblotted for pS6/S6, aAMPK
serine485/491/a2AMPK, and pThreonine172/a2AMPK or analyzed for a2AMPK activity. *p < 0.05 versus all other groups.
(F) GT1-7 neuronswere treatedwith rapamycin (7.5 nM; 30min) followed by 0.5 mg/ml leptin (+) or vehicle (–) for 2 hr and analyzed for a2AMPK activity and aAMPK
serine485/491/a2AMPK. p < 0.05 *versus all other groups; #versus no rapamycin (n = 8).
(G) The acute anorexigenic effect of leptin—from individual pathways to a unified signaling network in the hypothalamus. The gray dotted line indicates that
although our data do not support a direct effect of AKT to phosphorylate a2AMPK on serine 491 in the hypothalamus in response to acute leptin stimulation, this
site may be directly phosphorylated by AKT under other conditions or in response to other hormones or nutrients.
Data in all panels are shown as means ± SEM. See also Figure S4.
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p70S6 Kinase Is an Inhibitory AMPK KinaseThe mTOR-S6K pathway can play a role in both activation and
inhibition of hypothalamic AMPK and food intake because some
nutrient and hormonal signals such as feeding and branched
chain amino acids (e.g., leucine) activatemTOR-S6K in the hypo-
thalamus (Cota et al., 2006) while others suppress this pathway
(e.g., fasting). Our data showing that the PI3K-AKT-mTOR-
p70S6K pathway phosphorylates aAMPK on serine485/491 dem-
onstrate that these previously individual pathways in leptin
action form a unified signaling network in the hypothalamus to
mediate the acute anorexigenic and body weight effects of110 Cell Metabolism 16, 104–112, July 3, 2012 ª2012 Elsevier Inc.leptin (Figure 4G). This signaling network, which is implicated
in leptin’s acute effects (Hill et al., 2008; Niswender et al.,
2001), is likely to be complementary to the Stat3-mediated
more long-term regulation of food intake and body weight (Bates
et al., 2003; Myers et al., 2009).
Previous studies have shown that AKT can directly phosphor-
ylate aAMPK on serine485/491 (Horman et al., 2006; Soltys et al.,
2006). While this occurs under some conditions, our data show
that AKT does not mediate the effect of leptin to phosphorylate
aAMPK on serine485/491 because this phosphorylation is blocked
Cell Metabolism
p70S6 Kinase Is an Inhibitory AMPK Kinasewhen we inhibit S6K signaling with DN-S6K (Figure 4E) or
rapamycin (Figure 4F). This strongly suggests that in the leptin
signaling pathway, AKT is upstream of S6K and indirectly stimu-
lates S6K-dependent aAMPK serine485/491 phosphorylation (see
model, Figure 4G).
aAMPK serine485/491 phosphorylation may also be implicated
in multiple peripheral signals such as insulin and nutrients that
have previously been shown to modulate AMPK and mTOR in
the hypothalamus (Minokoshi et al., 2004; Cota et al., 2006).
Since PI3K, Akt, mTOR, and p70S6K have all been shown to
be important in cancer biology (Manning and Cantley, 2007),
this integration of these pathways may be important for cancer
and other human diseases and could lead to improved thera-
peutic approaches.EXPERIMENTAL PROCEDURES
Mice and Cells
Male FVB mice (age 8–9 weeks) were housed in a temperature-controlled
environment with a 14 hr/10 hr light/dark cycle and free excess to chow
diet (Formulab 5008; Farmer’s Exchange) and water before beginning exper-
iments. S6K1/ mice were a kind gift from Sarah Kozma and George
Thomas at the University of Cincinatti. Leptin (National Hormone and Peptide
Program) was injected i.c.v. (20 ng; 3 hr) 1 week after cannula insertion or i.p.
(5 mg/kg at 12 and 24 rh before sacrifice). Body weight and food intake
were monitored daily. Mice were sacrificed by decapitation and hypothalamic
nuclei were quickly dissected. All assays were performed on hypothalamic
regions from individual mice. All aspects of animal care were approved by
the Beth Israel Deaconess Medical Center Institutional Animal Care and
Use Committee.
GT1-7 cells were cultured at 37C with 5% CO2 in DMEM supplemented
with 10% heat-inactivated fetal bovine serum (FBS). Cells were transfected
with lipofectamine according to the manufacturer’s protocol. For leptin
studies, GT1-7 cells were serum starved overnight, exposed to 1 mM glucose
DMEMwithout FBS for 6 hr and than treated with leptin (0.5 mg/ml) for 2 hr. For
other studies, GT1-7 cells were serum starved overnight, and maintained in
5 mM glucose DMEM without FBS for 6 hr.
Surgery
i.c.v. cannulae were inserted in the third ventricle. Adenoviruses expressing
WT, S491A a2AMPK or control-empty vector were injected bilaterally (ante-
rior-posterior [AP] 1.40 mm, medial-lateral [ML] ± 0.5 mm from Bregma
and dorsal-ventral [DV] 5.5 mm from the brain surface) in the mediobasal
hypothalamus, consisting of the ARC, VMH, and DMH nuclei.
Perfusion and Sectioning
Mice were perfused transcardially with 0.9% saline, followed by 150 ml
10% formalin in 0.1 M phosphate-buffered saline (PBS) at pH 7.4. After over-
night fixation, the whole brains were cryoprotected in a solution of 30%
sucrose in 0.1 M PBS at pH 7.4. Serial coronal sections with 40 mm thickness
containing the hypothalamus were cut with a microtome and collected
in PBS.
Immunohistochemistry with Flag Antibody
Free-floating brain sections were incubated sequentially with (1) a primary
mouse antibody directed against FLAG M2 (Sigma) at 1:2,000 dilution in
0.1 M PBS with 0.3% Triton X-100 for two nights at 4C and (2) a secondary,
biotinylated donkey anti-mouse antibody (1:300 dilution in PBS; Jackson
Immunoresearch, West Grove, PA) for 2 and 3 hr, ABC Elite Kit (1:500; Vector
Laboratories, Burlingame, CA) for 2 hr. Then the sections were processed with
a mixture of diaminobenzidine (DAB; 0.2%), 0.05% hydrogen peroxide, and
0.6% nickel ammonium sulfate in 50 mM Tris buffer (pH 7.6).
After immunostaining, coronal brain sections were rinsed in PBS, mounted
serially, dehydrated, and then coverslipped with Permount.Dissection of Hypothalamic Regions
Each hypothalamic region was dissected from 1-mm-thick sagittal sections of
fresh brain. ARC, VMH/DMH, and PVN were dissected from the first sections
from the midline of the brain, and LH was dissected from the next lateral
sections. Coordinates for each hypothalamic region are as follows: PVN,
square area with anterior margin (posterior region of anterior commissure),
dorsal margin (border with thalamus), ventral margin (1.5 mm ventral to the
border with thalamus), and posterior margin (white matter separating PVN/
anterior hypothalamus and VMH/DMH); VMH/DMH, triangular area with
anterior margin (white matter separating PVH/anterior hypothalamus and
VMH/DMH), posterior margin (border with mammillary body), and ventral
margin (border with ARC); and ARC, ventral part of the medial hypothalamus
with anterior and dorsal margin (border with ventral part of VMH and DMH,
approximately 0.5 mm from the ventral surface of the medial hypothalamus)
and posterior margin (border with mammillary body). VMH and DMH were
collected from the triangular area with an anterior-dorsal margin of the white
matter separating PVN and the anterior hypothalamus from the VMH and
DMH, a ventral margin of the border with ARC.
a2AMPK Activity Measurement
a2AMPK activity was measured as described previously (Minokoshi et al.,
2004). In brief, a2 isoform-specific AMPK was immunoprecipitated from indi-
vidual hypothalamic nuclei andGT1-7 cell lysates with a specific a2AMPK anti-
body (Santa Cruz) bound to protein-G sepharose beads. The kinase activity of
the immunoprecipitates was measured with ‘‘SAMS’’ peptide and g-32P.
Immunoprecipitation and Western Blot Analysis
Individual hypothalamic nuclei andGT1-7 cell lysates were subjected to immu-
noprecipitation with a2AMPK antibody (Santa Cruz) and/or immunoblotted
with antibodies against pSerine485/491 and pThreonine172 AMPK, pSerine473
AKT, pThreonine389 p70S6K, pSerine240/244 S6, pTyrosine705 STAT3, pACC,
and ACC (all purchased from Cell Signaling). Protein levels were analyzed
with a2AMPK, b-actin (Santa Cruz), AKT, p70S6K, S6, and STAT3 (Cell
Signaling).
In Vitro Phosphorylation
Recombinant proteins were purchased from Signal-Chem (Richmond,
Canada). Recombinant a2AMPK/b1/g1 complex was incubated with recombi-
nant active p70S6K1 or with a negative control—recombinant inactive
p70S6K2 in 50 mM Na-HEPES, 5 mM MgCl2, 500 mM ATP, 1 mM DTT for
30 min at 30C.
qPCR Analysis of mRNA Levels of Neuropeptides
Total hypothalamic RNA was isolated with TriReagent according to the manu-
facturer’s instructions (Molecular Research Center, Cincinnati, OH). mRNAs of
AgRP and POMC were quantified by real-time reverse transcription-PCR
(RT-PCR) with the TaqMan one-step RT-PCR Master mix (Applied Biosys-
tems) and a Stratagene Mx3000P or Mx4000P system (Stratagene, La Jolla,
CA) as described previously (Minokoshi et al., 2004).
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.cmet.2012.05.010.
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